Clinical trial
Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and…
NCT00140556 · David M. Brizel, MD, Other · Completed
Key facts
| NCT number | NCT00140556 |
|---|---|
| Title | Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer |
| Official title | Concurrent Angiogenic and EGFR Blockade in Conjunction With Curative Intent Chemoradiation for Locally Advanced Head and Neck Cancer |
| Lead sponsor | David M. Brizel, MD, Other |
| Collaborators | Genentech, Inc. Industry OSI Pharmaceuticals |
| Status | Completed |
| Phase | Early Phase 1 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer, Pharynx Cancer |
| Intervention type | Drug, Radiation |
| Interventions | Chemoradiotherapy, Cisplatin, Bevacizumab, Erlotinib |
| Enrollment | 28 |
| Start date | Aug 1, 2005 |
| Primary completion | May 1, 2009 |
| Completion | Apr 1, 2010 |
| First posted | Sep 1, 2005 |
| Last update posted | Jan 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: